Last reviewed · How we verify
Placebo + valacyclovir
Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial.
Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial. Used for Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details).
At a glance
| Generic name | Placebo + valacyclovir |
|---|---|
| Sponsor | Candel Therapeutics, Inc. |
| Drug class | Antiviral nucleoside analog |
| Target | Herpes simplex virus DNA polymerase |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Valacyclovir is converted to acyclovir in vivo, which selectively inhibits viral DNA polymerase and prevents herpes simplex virus replication. In this phase 3 trial context, the placebo arm serves as a control to evaluate whether the antiviral component provides therapeutic benefit, likely in combination with an immunotherapeutic approach by Candel Therapeutics.
Approved indications
- Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details)
Common side effects
- Headache
- Nausea
- Renal dysfunction
- Thrombotic thrombocytopenic purpura (rare)
Key clinical trials
- Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy (PHASE2)
- Valacyclovir for Mild Cognitive Impairment (PHASE2)
- Aciclovir Versus Placebo for HSV-2 Meningitis (PHASE4)
- Anti-viral Therapy in Alzheimer's Disease (PHASE2)
- Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (PHASE2)
- Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PHASE3)
- Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth (NA)
- Valacyclovir in Pain Management of Acute Apical Abscesses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo + valacyclovir CI brief — competitive landscape report
- Placebo + valacyclovir updates RSS · CI watch RSS
- Candel Therapeutics, Inc. portfolio CI